125 related articles for article (PubMed ID: 36758322)
1. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
[TBL] [Abstract][Full Text] [Related]
2. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
3. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
4. Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26-30 and ≥31.
Berger NF; Zimmerman BS; Tharakan S; Suchman K; Cascetta KP; Blanter J; Moshier E; Ru M; Jaffer S; Tiersten A
Oncology; 2021; 99(11):699-702. PubMed ID: 34425579
[TBL] [Abstract][Full Text] [Related]
5. A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer.
Lee SB; Kim J; Sohn G; Kim J; Chung IY; Kim HJ; Ko BS; Son BH; Ahn SH; Lee JW; Jung KH
Cancer Res Treat; 2019 Jul; 51(3):1073-1085. PubMed ID: 30384581
[TBL] [Abstract][Full Text] [Related]
6. Trend and survival benefit of Oncotype DX use among female hormone receptor-positive breast cancer patients in 17 SEER registries, 2004-2015.
Zhang L; Hsieh MC; Petkov V; Yu Q; Chiu YW; Wu XC
Breast Cancer Res Treat; 2020 Apr; 180(2):491-501. PubMed ID: 32060781
[TBL] [Abstract][Full Text] [Related]
7. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
[TBL] [Abstract][Full Text] [Related]
8. Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data.
Orucevic A; Bell JL; McNabb AP; Heidel RE
Breast Cancer Res Treat; 2017 May; 163(1):51-61. PubMed ID: 28243897
[TBL] [Abstract][Full Text] [Related]
9. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results.
Singh K; He X; Kalife ET; Ehdaivand S; Wang Y; Sung CJ
Breast Cancer Res Treat; 2018 Feb; 168(1):29-34. PubMed ID: 29230662
[TBL] [Abstract][Full Text] [Related]
10. The effect of Oncotype DX
Rabie MA; Rankin A; Burger A; Youssef M
Ann R Coll Surg Engl; 2019 Nov; 101(8):596-601. PubMed ID: 31219316
[TBL] [Abstract][Full Text] [Related]
11. Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative ≤ T1b Breast Cancer.
Pomponio M; Keele L; Hilt E; Burkbauer L; Goldbach M; Nazarian S; Fox K; Tchou J
Ann Surg Oncol; 2020 May; 27(5):1671-1678. PubMed ID: 31686348
[TBL] [Abstract][Full Text] [Related]
12. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
13. Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.
Kozick Z; Hashmi A; Dove J; Hunsinger M; Arora T; Wild J; Shabahang M; Blansfield J
Am J Surg; 2018 Apr; 215(4):686-692. PubMed ID: 28606707
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx.
Sughayer MA; Alhassoon S; Sughayer HM
Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX
Turner BM; Gimenez-Sanders MA; Soukiazian A; Breaux AC; Skinner K; Shayne M; Soukiazian N; Ling M; Hicks DG
Cancer Med; 2019 Aug; 8(9):4176-4188. PubMed ID: 31199586
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the Management of Early Breast Cancer.
Hillyar C; Rizki H; Abbassi O; Miles-Dua S; Clayton G; Gandamihardja T; Smith S
Cureus; 2020 Apr; 12(4):e7552. PubMed ID: 32382456
[TBL] [Abstract][Full Text] [Related]
17. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
Glasgow A; Sechrist H; Bomeisl P; Gilmore H; Harbhajanka A
Breast Cancer; 2021 Mar; 28(2):321-328. PubMed ID: 32951186
[TBL] [Abstract][Full Text] [Related]
18. Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study.
Acuna N; Plascak JJ; Tsui J; Stroup AM; Llanos AAM
Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34065945
[TBL] [Abstract][Full Text] [Related]
19. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
20. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset.
Harowicz MR; Robinson TJ; Dinan MA; Saha A; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2017 Feb; 162(1):1-10. PubMed ID: 28064383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
